New hope for Tough-to-Treat breast cancer: major trial tests promising drug
NCT ID NCT06957886
Summary
This large, late-stage trial is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-low breast cancer that has returned or spread. It will involve 566 participants to see if the new treatment helps patients live longer without their cancer getting worse. The study will also closely monitor side effects to understand the drug's safety profile.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, China
Contact
Conditions
Explore the condition pages connected to this study.